Changes in the Th1/Th2 ratio during a 24‐week course of an interferon alpha‐2b plus ribavirin combination therapy for patients with chronic hepatitis C

Fujimoto, Tomoko; Tomimatsu, Masahiko; Iga, Daijiro; Endo, Hitoshi; Otsuka, Kuniaki

doi:10.1111/j.1440-1746.2008.05320.x

Cited by 7 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially, it was reported that ribavirin enhances production of T helper 1 (Th1) cytokines such as IFN-γ, TNF-α and IL-2, while suppressing T helper 2 (Th2) cytokines such as IL-4, IL-5 and IL-10 (11,12). However, contradictory results have been reported by other studies (13), thus T cell-regulatory roles of ribavirin are still controversial (14). …”

Section: Introductionmentioning

confidence: 93%

Ribavirin Does Not Impair the Suppressive Activity of Foxp3⁺CD4⁺CD25⁺Regulatory T Cells

2013

View full text Add to dashboard Cite

Ribavirin is an antiviral drug used in combination with pegylated interferon-α (IFN-α) for the treatment of hepatitis C virus (HCV) infection. Recently, ribavirin was reported to inhibit the suppressive activity of regulatory T (Treg) cells. In the present study, we re-evaluated the effect of ribavirin on Foxp3+CD4+CD25+ Treg cells from normal donors. First, we examined the expression of CTLA-4 and CD39, which are known to play a role in the suppressive function of Treg cells. We found that ribavirin treatment did not modulate the expression of CTLA-4 and CD39 in Treg cells. We also studied the effect of ribavirin on Treg cells in the presence of IFN-α; however, the expression of CTLA-4 and CD39 in Treg cells was not changed by ribavirin in the presence of IFN-α. Next, we directly evaluated the effect of ribavirin on the suppressive activity of Treg cells in the standard Treg suppression assay, by co-culturing CFSE-labeled non-Treg CD4+ T cells with purified Treg cells. We found that ribavirin did not attenuate the suppressive activity of Treg cells. Taken together, while ribavirin reversed Treg cell-mediated suppression of effector T cells in the previous study, we herein demonstrate that ribavirin does not impair the suppressive activity of Treg cells.

show abstract

Section: Introductionmentioning

confidence: 93%

Ribavirin Does Not Impair the Suppressive Activity of Foxp3⁺CD4⁺CD25⁺Regulatory T Cells

2013

View full text Add to dashboard Cite

show abstract

“…Several studies showed an association between the abundance of TCD8+ cells and SVR 14,22 , and the quality of the T helper (Th)1 response in the baseline period, and the increase in Th2 cytokines during treatment may define treatment success or failure 11,14,23,24 . These studies were performed on patients treated with dual therapy (IFN alpha or PegIFN and RBV).…”

Section: Introductionmentioning

confidence: 99%

Influence of the inflammatory response on treatment of hepatitis C with triple therapy

Winckler

Braz

Silva

et al. 2018

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Chronic hepatitis C is a leading cause of liver disease. Infection triggers an immediate immune response in the host that is mediated by humoral/cellular mechanisms. T cells respond to infection via secretion of cytokines, which inhibit or stimulate one another, leading to cytokine imbalance and ultimately affecting treatment. Studies using interferon (IFN) and ribavirin (RBV) showed that TCD8+ cells and cytokine levels are associated with sustainable virological response (SVR). However, studies that investigated the effects of triple therapy (TT) are limited. Methods: The study included hepatitis C virus (HCV)+ RNA, naives, genotype 1, ≥18 years, and advanced fibrosis (F≥3) patients. Samples were collected at baseline and after 12 weeks (W12) of TT. Six cytokines were analyzed by flow cytometry. Results: Of 31 patients, four were excluded (two deaths, one interrupted TT, and one F2 patient). Of the 27 remaining patients, 21 (78%) were cirrhotic. SVR was achieved in 63% of the patients. The patients had a mean age of 55.11 ± 10.03 years. Analyses at baseline showed that the chemokine CCL5/Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) (p=0.04) and interleukin (IL)-6 (p=0.02), which was associated with SVR. RANTES (p=0.04) and IL-8 (p=0.01) levels were associated with SVR at W12. Conclusions: Similar to patterns observed during double therapy, IL-6, IL-8, and RANTES levels were associated with SVR in TT, indicating the potential role of interferon in immune response to hepatitis C virus.

show abstract

“…Moreover, HCV treatment has been demonstrated to lead to lymphocyte polarization towards Th1 over Th2, a mechanism implicated in the pathogenesis of PBC. 8 Some obscure points need to be considered. For example, normal alkaline phosphatase levels are unusual in PBC, but some reports in literature have highlighted this eventuality.…”

mentioning

confidence: 99%

Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept

Rendina

Castellaneta

Losurdo

et al. 2018

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Changes in the Th1/Th2 ratio during a 24‐week course of an interferon alpha‐2b plus ribavirin combination therapy for patients with chronic hepatitis C

Abstract: The significant changes in the Th2 level correlated with the therapeutic effect during the IFN alpha-2b plus ribavirin combination therapy. The increase of the Th2 level during therapy could be a predictor for achieving SVR.

Cited by 7 publications

References 20 publications

Ribavirin Does Not Impair the Suppressive Activity of Foxp3⁺CD4⁺CD25⁺Regulatory T Cells

Ribavirin Does Not Impair the Suppressive Activity of Foxp3⁺CD4⁺CD25⁺Regulatory T Cells

Influence of the inflammatory response on treatment of hepatitis C with triple therapy

Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept

Contact Info

Product

Resources

About

Changes in the Th1/Th2 ratio during a 24‐week course of an interferon alpha‐2b plus ribavirin combination therapy for patients with chronic hepatitis C

Abstract: The significant changes in the Th2 level correlated with the therapeutic effect during the IFN alpha-2b plus ribavirin combination therapy. The increase of the Th2 level during therapy could be a predictor for achieving SVR.

Cited by 7 publications

References 20 publications

Ribavirin Does Not Impair the Suppressive Activity of Foxp3+CD4+CD25+Regulatory T Cells

Ribavirin Does Not Impair the Suppressive Activity of Foxp3+CD4+CD25+Regulatory T Cells

Influence of the inflammatory response on treatment of hepatitis C with triple therapy

Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept

Contact Info

Product

Resources

About

Ribavirin Does Not Impair the Suppressive Activity of Foxp3⁺CD4⁺CD25⁺Regulatory T Cells

Ribavirin Does Not Impair the Suppressive Activity of Foxp3⁺CD4⁺CD25⁺Regulatory T Cells